In:
Tumori Journal, SAGE Publications, Vol. 106, No. 4 ( 2020-08), p. 306-311
Abstract:
The immune checkpoint ligand, programmed cell death 1 ligand 1 (PD-L1), is expressed in various tumors and associated with response to drugs that target programmed cell death protein 1. Previous studies have estimated the level of PD-L1 expression among different stages of thymoma and thymic carcinoma to evaluate its potential use as a diagnostic factor; however, its varying expression level has been problematic. We conducted this meta-analysis of published literature to evaluate PD-L1 expression in thymomas and thymic carcinomas. Methods: We analyzed 12 studies that included 320 patients with type A/AB/B1 thymoma, 225 patients with type B2/B3 thymoma, and 180 patients with thymic carcinoma. Results: No difference in PD-L1 expression level was found between the B2/B3 vs C groups (odds ratio [OR], 0.67; 95% confidence interval [CI] , 0.26, 1.76; p = 0.42). However, the heterogeneity was very high ( I 2 = 78%), and a significant difference was found between groups A/AB/B1 and B2/B3 (OR, 0.22; 95% CI, 0.12, 0.41; p 〈 0.001), with a relatively low heterogeneity ( I 2 = 55%). Conclusion: PD-L1 positivity might be a useful factor to differentiate type A/AB/B1 thymoma from type B2/B3 and thymic carcinoma. This result might be valuable for potential anti PD-L1 treatment in thymoma and thymic carcinoma.
Type of Medium:
Online Resource
ISSN:
0300-8916
,
2038-2529
DOI:
10.1177/0300891620915788
Language:
English
Publisher:
SAGE Publications
Publication Date:
2020
detail.hit.zdb_id:
280962-X
detail.hit.zdb_id:
2267832-3
Bookmarklink